PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bttDove Medical PressThis ArticleSubscribeSubmit a ManuscriptSearchFollowDovepressBiologics: Targets and Therapy
 
Biologics. 2012; 6: 137–146.
Published online Jun 20, 2012. doi:  10.2147/BTT.S23917
PMCID: PMC3395896
Metastatic gastric cancer – focus on targeted therapies
Judith Meza-Junco and Michael B Sawyer
Department of Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada
Correspondence: Judith Meza-Junco, Department of Oncology, University of Alberta Cross Cancer Institute, 11560 University Avenue, Edmonton T6G 1Z2, Alberta, Canada, Tel +1 780 577 8125, Fax +1 780 432 8888, Email j udith.meza-junco/at/albertahealthservices.ca
Abstract
Gastric cancer (GC) is currently the second leading cause of cancer death worldwide; unfortunately, most patients will present with locally advanced or metastatic disease. Despite recent progress in diagnosis, surgery, chemotherapy, and radiotherapy, prognosis remains poor. A better understanding of GC biology and signaling pathways is expected to improve GC therapy, and the integration of targeted therapies has recently become possible and appears to be promising. This article focuses on anti-Her-2 therapy, specifically trastuzumab, as well as other epidermal growth factor receptor antagonists such as cetuximab, panitumub, matuzumab, nimotzumab, gefitinib, and erlotinib. Additionally, drugs that target angiogenesis pathways are also under investigation, particulary bevacizumab, ramucirumab, sorafenib, sunitinib, and cediranib. Other targeted agents in preclinical or early clinical development include mTOR inhibitors, anti c-MET, polo-like kinase 1 inhibitors, anti-insulin-like growth factor, anti-heat shock proteins, and small molecules targeting Hedgehog signaling.
Keywords: gastric cancer, targeted therapy, antiangiogenesis drugs, anti-EGFR drugs
Articles from Biologics : Targets & Therapy are provided here courtesy of
Dove Press